bullish
Takeda Offloads Asia-Focused Drugs to South Korea’s Celltrion
347 Views12 Jun 2020 16:26
The Japanese drug maker, Takeda Pharmaceutical (4502 JP) announced yesterday (11th June 2020) that it has entered into an agreement to divest a...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
- Hygeia Healthcare IPO (Part II): Healthy Valuation17 Jun 2020
- Hygeia Healthcare IPO (Part I): A Better Healthcare16 Jun 2020
- Fujifilm Invests US$928m to Expand Its Bio-CDMO Capacity16 Jun 2020
- Takeda Offloads Asia-Focused Drugs to South Korea’s Celltrion12 Jun 2020
- Jio Bags More Foreign Investors; What’s Next?08 Jun 2020
- Vodafone Idea: Google Now Explores Buying a Stake in Vodafone’s India Business29 May 2020
- Takeda Pharma Divests Yet Another Non-Core Asset to Pay-Off Debt and Focus on Core Areas29 Apr 2020
x